[Quantification of hepatitis B virus HBsAg: clinical implications]

Area of Science:

• Hepatology
• Virology
• Immunology

Background:

• Hepatitis B surface antigen (HBsAg) is a key marker for hepatitis B virus (HBV) infection.
• Quantification of HBsAg levels is increasingly important with available commercial tests.
• HBsAg quantification has shown prognostic value in specific treatment regimens.

Purpose of the Study:

• To review the significance of HBsAg quantification in managing HBV infection.
• To evaluate the predictive role of HBsAg levels in different antiviral therapies.
• To highlight areas requiring further investigation regarding HBsAg quantification.

Main Methods:

• Literature review of studies on HBsAg quantification and HBV treatment.
• Analysis of findings from clinical trials involving pegylated interferon alfa and nucleoside analogues.
• Synthesis of current understanding and identification of knowledge gaps.

Main Results:

• Decreased HBsAg levels during pegylated interferon alfa treatment correlate with HBsAg loss and sustained virologic response.
• The prognostic value of HBsAg quantification in patients receiving nucleoside analogue therapy is not well-established.
• Further research is needed to clarify the role of HBsAg quantification with nucleoside analogues.

Conclusions:

• HBsAg quantification is a valuable tool for monitoring treatment efficacy in HBV infection.
• Its predictive power is demonstrated with interferon-based therapies.
• The utility of HBsAg quantification with nucleoside analogues warrants further investigation.